• About us
  • Science and Pipeline
  • Investors
  • Contact us
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 23, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – December 23, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the...

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024 | Press Releases

Marlborough, Massachusetts–(Newsfile Corp. – December 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biotechnology company that develops therapeutics using its INTASYL® siRNA gene silencing technology to make the...

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 19, 2024 | Press Releases

Phio’s Lead Compound PH-762 demonstrates encouraging safety profile in 2nd cohort with recommendation to escalate to next dose concentrationMarlborough, Massachusetts–(Newsfile Corp. – December 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ:...

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 12, 2024 | Press Releases

Journal is the official publication of the International Union of Immunological SocietiesMarlborough, Massachusetts–(Newsfile Corp. – December 12, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing...

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Dec 10, 2024 | Press Releases

Award is being presented during Advanced Therapies Week 2025 in DallasMarlborough, Massachusetts–(Newsfile Corp. – December 10, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO),) is a clinical-stage biotechnology company developing therapeutics that...

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Dec 3, 2024 | Press Releases

Registration Link for Presentation and live Q&A to take place, Tuesday, December 10, 2024 at 12:00 pm ESTMarlborough, Massachusetts–(Newsfile Corp. – December 3, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology...
« Older Entries
Next Entries »

Recent Posts

  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
  • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
  • Phio Pharmaceuticals to Present at the Life Sciences Future Conference
  • Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference
  • Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Recent Comments

No comments to show.
Email Alerts

Stay up to date on news and investor alerts

Sign up now

© 2025 Phio Pharmaceuticals

  • Follow
  • Follow
  • Home
  • About us
  • Science and Pipeline
  • Investors
  • Contact us